G试验影响因素分析

doi:10.3969/j.issn.1673-8640.2023.08.017

摘要/Abstract

摘要：

近年来，免疫抑制和危重患者IFD发生率持续上升。早期诊断IFD对降低患者死亡率、改善预后具有十分重要的意义。G试验是早期诊断侵袭性真菌病（IFD）重要的血清学方法之一，目前已广泛应用于临床。然而，医源性污染、细菌感染、肠道黏膜受损会导致G试验结果假阳性；抗真菌药物治疗、突破性念珠菌感染等会导致G试验结果假阴性。文章对G试验的影响因素进行综述，以帮助临床和实验室正确根据G试验结果及时制定相应的治疗策略。

关键词: 侵袭性真菌病, 1, 3-β-D-葡聚糖, G试验, 假阳性, 假阴性

Abstract:

G assay is one of the most important serological methods for the early diagnosis of invasive fungal disease（IFD）. Nowadays it is widely used in clinical practice. However，medical contamination，bacterial infection and intestinal mucosal damage can lead to false positivity of G assay results. The use of antifungal drug and breakthrough Candida infection can lead to false negativity of G assay results. In addition，as the proportion of immunosuppressed and critical patients suffering from IFD continues to increase，early diagnosis of IFD is of importance to reduce mortality and improve the prognosis of those patients. This review focuses on the factors influencing G assay to give proper guidance of the use of G assay both in clinical practice and in laboratory，as well as the corresponding countermeasures.

Key words: Invasive fungal disease, 1, 3-Beta-D-glucan, G assay, False positivity, False negativity

中图分类号:

R446.1

方文东, 王友亮, 陈水平. G试验影响因素分析[J]. 检验医学, 2023, 38(8): 796-799.

FANG Wendong, WANG Youliang, CHEN Shuiping. Analysis on influencing factors of G assay[J]. Laboratory Medicine, 2023, 38(8): 796-799.

参考文献 37

[1]	PERSON A K, KONTOYIANNIS D P, ALEXANDER B D. Fungal infections in transplant and oncology patients[J]. Hematol Oncol Clin North Am, 2011, 25(1):193-213. DOI URL
[2]	BARTON R C. Laboratory diagnosis of invasive aspergillosi:from diagnosis to prediction of outcome[J]. Scientifica(Cairo), 2013, 2013:459405.
[3]	DE PAUW B, WALSH T J, DONNELLY J P, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/invasive fungal infections cooperative group and the national institute of allergy and infectious diseases Mycoses Study Group(EORTC/MSG)consensus group[J]. Clin Infect Dis, 2008, 46(12):1813-1821. DOI URL
[4]	TALENTO A F, DUNNE K, JOYCE E A, et al. A prospective study of fungal biomarkers to improve management of invasive fungal diseases in a mixed specialty critical care unit[J]. J Crit Care, 2017, 40:119-127. DOI PMID
[5]	ROSE S R, VALLABHAJOSYULA S, VELEZ M G, et al. The utility of bronchoalveolar lavage beta-D-glucan testing for the diagnosis of invasive fungal infections[J]. J Infect, 2014, 69(3):278-283. DOI PMID
[6]	RHEIN J, BAHR N C, MORAWSKI B M, et al. Detection of high cerebrospinal fluid levels of(1→3)-β-D-glucan in cryptococcal meningitis[J]. Open Forum Infect Dis, 2014, 1(3):ofu105. DOI URL
[7]	KARAGEORGOPOULOS D E, VOULOUMANOU E K, NTZIORA F, et al. β-D-glucan assay for the diagnosis of invasive fungal infections:a meta-analysis[J]. Clin Infect Dis, 2011, 52(6):750-770. DOI URL
[8]	FINKELMAN M A. Specificity influences in(1→3)-β-D-glucan-supported diagnosis of invasive fungal disease[J]. J Fungi(Basel), 2020, 7(1):14.
[9]	LISS B, CORNELY O A, HOFFMANN D, et al. 1,3-β-D-glucan contamination of common antimicrobials[J]. J Antimicrob Chemother, 2016, 71(4):913-915. DOI PMID
[10]	MARTY F M, LOWRY C M, LEMPITSKI S J, et al. Reactivity of(1→3)-β-D-glucan assay with commonly used intravenous antimicrobials[J]. Antimicrob Agents Chemother, 2006, 50(10):3450-3453. DOI URL
[11]	MENNINK-KERSTEN M A, WARRIS A, VERWEIJ P E. 1,3-β-D-glucan in patients receiving intravenous amoxicillin-clavulanic acid[J]. N Engl J Med, 2006, 354(26):2834-2835. DOI URL
[12]	RACIL Z, KOCMANOVA I, LENGEROVA M, et al. Difficulties in using 1,3-β-D-glucan as the screening test for the early diagnosis of invasive fungal infections in patients with haematological malignancies-high frequency of false-positive results and their analysis[J]. J Med Microbiol, 2010, 59(9):1016-1022. DOI URL
[13]	METAN G, AGKUS C, NEDRET K A, et al. Does ampicillin-sulbactam cause false positivity of(1,3)-beta-D-glucan assay?A prospective evaluation of 15 patients without invasive fungal infections[J]. Mycoses, 2012, 55(4):366-371. DOI URL
[14]	ISHIZUKA Y, TSUKADA H, GEJYO F. Interference of(1→3)-β-D-glucan administration in the measurement of plasma(1→3)-β-D-glucan[J]. Intern Med, 2004, 43(2):97-101. DOI URL
[15]	SCHROEDER I, DICHTL K, LIEBCHEN U, et al. Digestive enzymes of fungal origin as a relevant cause of false positive Aspergillus antigen testing in intensive care unit patients[J]. Infection, 2021, 49(2):241-248. DOI
[16]	LISS B, CORNELY O A, HOFFMANN D, et al. 1,3-β-D-glucan concentrations in blood products predict false positive post-transfusion results[J]. Mycoses, 2016, 59(1):39-42. DOI URL
[17]	BOUGNOUX M E, ANGEBAULT C, PACCOUD O, et al. Impact of intravenous and subcutaneous immunoglobulins on false positivity of galactomannan and β-D-glucan antigenaemia and detection of circulating Aspergillus fumigatus DNA[J]. Clin Microbiol Infect, 2020, 26(8):1101-1102. DOI URL
[18]	EGGER M, PRÜLLER F, RAGGAM R, et al. False positive serum levels of(1-3)-β-D-glucan after infusion of intravenous immunoglobulins and time to normalisation[J]. J Infect, 2018, 76(2):206-210. DOI URL
[19]	KANDA H, KUBO K, HAMASAKI K, et al. Influence of various hemodialysis membranes on the plasma(1→3)-beta-D-glucan level[J]. Kidney Int, 2001, 60(1):319-323. DOI URL
[20]	PRATTES J, SCHNEDITZ D, PRÜLLER F, et al. 1,3-β-D-glucan testing is highly specific in patients undergoing dialysis treatment[J]. J Infect, 2017, 74(1):72-80. DOI URL
[21]	VIGOR K, EMERSON J, SCOTT R, et al. Development of downstream processing to minimize beta-glucan impurities in GMP-manufactured therapeutic antibodies[J]. Biotechnol Prog, 2016, 32(6):1494-1502. DOI URL
[22]	KANAMORI H, KANEMITSU K, MIYASAKA T, et al.Measurement of(1-3)-β-D-glucan derived from different gauze types[J]. Tohoku J Exp Med, 2009, 217(2):117-121. DOI URL
[23]	SZYSZKOWITZ A, ZURL C, HERZEG A, et al. Serum 1,3-beta-D-glucan values during and after laparoscopic and open intestinal surgery[J]. Open Forum Infect Dis, 2018, 5(12):ofy296. DOI URL
[24]	SHUPP J W, PETRAITIENE R, JASKILLE A D, et al. Early serum(1→3)-β-D-glucan levels in patients with burn injury[J]. Mycoses, 2012, 55(3):224-227. DOI URL
[25]	MENNINK-KERSTEN M A, VERWEIJ P E. Non-culture-based diagnostics for opportunistic fungi[J]. Infect Dis Clin North Am, 2006, 20(3):711-727. DOI URL
[26]	LEQUETTE Y, ROLLET E, DELANGLE A, et al. Linear osmoregulated periplasmic glucans are encoded by the opgGH locus of Pseudomonas aeruginosa[J]. Microbiology(Reading), 2007, 153(Pt 10):3255-3263.
[27]	KOYA J, NANNYA Y, KOBAYASHI H, et al. Simultaneous increase in 1,3-β-D-glucan and procalcitonin levels in Pseudomonas aeruginosa infection[J]. J Infect, 2013, 67(2):164-166. DOI URL
[28]	ALBERT O, TOUBAS D, STRADY C, et al. Reactivity of(1→3)-β-D-glucan assay in bacterial bloodstream infections[J]. Eur J Clin Microbiol Infect Dis, 2011, 30(11):1453-1460. DOI URL
[29]	SAWAI T, NAKAO T, YAMAGUCHI S, et al. Detection of high serum levels of β-D-glucan in disseminated nocardial infection:a case report[J]. BMC Infect Dis, 2017, 17(1):272. DOI URL
[30]	LEELAHAVANICHKUL A, WORASILCHAI N, WANNALERDSAKUN S, et al. Gastrointestinal leakage detected by serum(1→3)-β-D-glucan in mouse models and a pilot study in patients with sepsis[J]. Shock, 2016, 46(5):506-518. DOI URL
[31]	ISSARA-AMPHORN J, SURAWUT S, WORASILCHAI N, et al. The synergy of endotoxin and(1→3)-β-D-glucan,from gut translocation,worsens sepsis severity in a lupus model of Fc gamma receptor,Ⅱb-deficient mice[J]. J Innate Immun, 2018, 10(3):189-201. DOI URL
[32]	HASHIMOTO N, MORI T, HASHIDA R, et al. False-positive serum(1,3)-β-D-glucan elevation due to intake of seaweed in a hematopoietic stem cell transplant recipient[J]. Transpl Infect Dis, 2017, 19(2).
[33]	ELIZAQUÍVEL P, SÁNCHEZ G, SALVADOR A, et al. Evaluation of yogurt and various beverages as carriers of lactic acid bacteria producing 2-branched(1,3)-β-D-glucan[J]. J Dairy Sci, 2011, 94(7):3271-3278. DOI URL
[34]	PICKERING J W, SANT H W, BOWLES C A, et al.Evaluation of a(1→3)-β-D-glucan assay for diagnosis of invasive fungal infections[J]. J Clin Microbiol, 2005, 43(12):5957-5962. DOI URL
[35]	CURTO M Á, BUTASSI E, RIBAS J C, et al. Natural products targeting the synthesis of β(1,3)-D-glucan and chitin of the fungal cell wall. Existing drugs and recent findings[J]. Phytomedicine, 2021, 88:153556. DOI URL
[36]	ABE M, KIMURA M, ARAOKA H, et al. Serum(1,3)-beta-D-glucan is an inefficient marker of breakthrough candidemia[J]. Med Mycol, 2014, 52(8):835-840. DOI URL
[37]	PICKERING J W, SANT H W, BOWLES C A, et al. Evaluation of a (1->3)-beta-D-glucan assay for diagnosis of invasive fungal infections[J]. J Clin Microbiol, 2005, 43(12):5957-5962. DOI URL